Niaprazine | CAS#27367-90-4

MedKoo Cat#: 535091 | Name: Niaprazine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Niaprazine is a selective brain catecholamine depletor.

Chemical Structure

Niaprazine

CAS#27367-90-4

Theoretical Analysis

MedKoo Cat#: 535091

Name: Niaprazine

CAS#: 27367-90-4

Chemical Formula: C20H25FN4O

Exact Mass: 356.2012

Molecular Weight: 356.45

Elemental Analysis: C, 67.39; H, 7.07; F, 5.33; N, 15.72; O, 4.49

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Niaprazine

IUPAC/Chemical Name

N-(3-(4-(4-Fluorophenyl)-1-piperazinyl)-1-methylpropyl)-3-pyridinecarboxamide

InChi Key

RSKQGBFMNPDPLR-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H25FN4O/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26)

SMILES Code

O=C(C1=CC=CN=C1)NC(C)CCN2CCN(C3=CC=C(F)C=C3)CC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 356.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Keane PE, Strolin Benedetti M, Dow J. The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain. Neuropharmacology. 1982 Feb;21(2):163-9. doi: 10.1016/0028-3908(82)90157-5. PMID: 6460945. 2: Rossi PG, Posar A, Parmeggiani A, Pipitone E, D'Agata M. Niaprazine in the treatment of autistic disorder. J Child Neurol. 1999 Aug;14(8):547-50. doi: 10.1177/088307389901400814. PMID: 10456769. 3: Pisciotta L, Gherzi M, Stagnaro M, Calevo MG, Giannotta M, Vavassori MR, Veneselli E; I.B.AHC Consortium, De Grandis E. Alternating Hemiplegia of Childhood: Pharmacological treatment of 30 Italian patients. Brain Dev. 2017 Jun;39(6):521-528. doi: 10.1016/j.braindev.2017.02.001. Epub 2017 Feb 27. PMID: 28249736. 4: Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF. Molecular pharmacology of niaprazine. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):989-1001. doi: 10.1016/0278-5846(88)90093-0. PMID: 2853885. 5: Niederhofer H. Niaprazine may improve some symptoms of attention-deficit hyperactivity disorder. Minerva Pediatr. 2010 Apr;62(2):231-2. PMID: 20440244. 6: Franzoni E, Masoni P, Mambelli M, Marzano P, Donati C. La niaprazina nei disturbi del comportamento del bambino. Confronto in doppio cieco contro placebo [Niaprazine in behavior disorders in children. Double-blind comparison with placebo]. Pediatr Med Chir. 1987 Mar-Apr;9(2):185-7. Italian. PMID: 2958783. 7: Keane PE, Benedetti MS. Niaprazine, a selective brain catecholamine depletor. Neuropharmacology. 1979 Jul;18(7):595-600. doi: 10.1016/0028-3908(79)90110-2. PMID: 158713. 8: Pozzi M, Conti V, Locatelli F, Galbiati S, Radice S, Clementi E, Strazzer S. Paroxysmal Sympathetic Hyperactivity in Pediatric Rehabilitation: Pathological Features and Scheduled Pharmacological Therapies. J Head Trauma Rehabil. 2017 Mar/Apr;32(2):117-124. doi: 10.1097/HTR.0000000000000255. PMID: 27603764. 9: Montanari G, Schiaulini P, Covre A, Steffan A, Furlanut M. Niaprazine vs chlordesmethyldiazepam in sleep disturbances in pediatric outpatients. Pharmacol Res. 1992 Feb-Mar;25 Suppl 1:83-4. doi: 10.1016/1043-6618(92)90551-l. PMID: 1354861. 10: Ottaviano S, Giannotti F, Cortesi F. The effect of niaprazine on some common sleep disorders in children. A double-blind clinical trial by means of continuous home-videorecorded sleep. Childs Nerv Syst. 1991 Oct;7(6):332-5. doi: 10.1007/BF00304832. PMID: 1837245. 11: Bodiou C, Bavoux F. Niaprazine et effets indésirables en pédiatrie. Bilan coopératif des centres français de pharmacovigilance [Niaprazine and side effects in pediatrics. Cooperative evaluation of French centers of pharmacovigilance]. Therapie. 1988 Jun-Jul;43(4):307-11. French. PMID: 2903572. 12: Sarda H, Benkhelifa S, Housset C, Le Loc'h H. Malaise après niaprazine (Nopron) [Syncope after niaprazine (Nopron)]. Arch Pediatr. 1996 Jan;3(1):90. French. doi: 10.1016/s0929-693x(96)80020-0. PMID: 8745837. 13: Duchene-Marullaz P, Rispat G, Perriere JP, Hache J, Labrid C. De quelques propriétés pharmacodynamiques de la niaprazine, nouvel antihistaminique [Some pharmacodynamical properties of niaprazine, a new antihistaminic agent]. Therapie. 1971 Nov-Dec;26(6):1203-9. French. PMID: 4401719. 14: Auduy B. Défaillance cardio-respiratoire aiguë après absorption de niaprazine [Acute cardio-respiratory failure after niaprazine absorption]. Arch Fr Pediatr. 1988 Jun-Jul;45(6):439. French. PMID: 2905885. 15: Veneselli E, Biancheri R. Alternating hemiplegia of childhood: treatment of attacks with chloral hydrate and niaprazine. Eur J Pediatr. 1997 Feb;156(2):157-8. PMID: 9039526. 16: Younus M, Labellarte MJ. Insomnia in children: when are hypnotics indicated? Paediatr Drugs. 2002;4(6):391-403. doi: 10.2165/00128072-200204060-00006. PMID: 12038875. 17: Lee W, Day TJ, Williams DR. Clinical, laboratory and electrophysiological features of Morvan's fibrillary chorea. J Clin Neurosci. 2013 Sep;20(9):1246-9. doi: 10.1016/j.jocn.2012.10.029. Epub 2013 May 24. PMID: 23712055. 18: Dostert P, Strolin Benedetti M, Rovei V, Smith RL. Can a 1,2-oxygen shift of a nicotinamide N-oxide derivative occur in vivo? Xenobiotica. 1985 Oct;15(10):799-803. doi: 10.3109/00498258509045031. PMID: 2933883. 19: Mancini J, Thirion X, Masut A, Saillard C, Pradel V, Romain F, Pastor MJ, Coudert C, Micallef J. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):494-503. doi: 10.1002/pds.1258. PMID: 16700077. 20: De Zen L, Del Rizzo I, Robazza M, Barbieri F, Campagna M, Vaccher S, Barbi E, Dall'Amico R. Home Use of Intranasal Dexmedetomidine in a Child With An Intractable Sleep Disorder. J Pediatr Pharmacol Ther. 2020;25(4):332-335. doi: 10.5863/1551-6776-25.4.332. PMID: 32461748; PMCID: PMC7243900.